论文信息 - Commentary: Science Scandal or Ethics Scandal? Olivieri Redux

Commentary: Science Scandal or Ethics Scandal? Olivieri Redux

Dr. Nancy Olivieri has become an icon of research integrity for her insistence on publishing adverse data about a drug she was investigating. She has been celebrated world-wide as a hero of biomedical ethics for her bravery in disclosing potential dangers to research subjects, in the face of both drug company threats and coercive pressures from her hospital and university. Like so many other 'whistle-blowers' however, she now faces both personal vilification and disturbing accusations of scientific error. The case against Olivieri is assessed and found to be baseless.

A. Schafer

[1] K. Carmichael. The Drug Trial: Nancy Olivieri and the Science Scandal That Rocked the Hospital for Sick Children , 2005, Annals of Internal Medicine.

[2] D. Healy,et al. Antidepressant drug use & the risk of suicide , 2005, International review of psychiatry.

[3] W. Kondro. Drug company experts advised staff to withhold data about SSRI use in children , 2004, Canadian Medical Association Journal.

[4] G. Brittenham,et al. Deferiprone and hepatic fibrosis. , 2003, Blood.

[5] D. Weatherall,et al. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility , 2003, The Lancet.

[6] T. S. St. Pierre. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. , 2003, Lancet.

[7] D. Weatherall,et al. Academic freedom in clinical research. , 2002, The New England journal of medicine.

[8] G. D’Amico,et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. , 2002, Blood cells, molecules & diseases.

[9] R. Lindeman,et al. The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). , 2000, Transfusion science.

[10] K. Fleming,et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. , 1998, The New England journal of medicine.